Cargando…
Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety‐one patients with CML and 76 controls were included and in total 4 (4...
Autores principales: | Winkelmann, Nina, Schwarz, Michaela, Hildebrandt, Bert, Henke, Oliver, Bullinger, Lars, Na, Il‐Kang, Stintzing, Sebastian, le Coutre, Philipp |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422034/ https://www.ncbi.nlm.nih.gov/pubmed/36051062 http://dx.doi.org/10.1002/jha2.502 |
Ejemplares similares
-
Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort
por: Lackamp, Nadine, et al.
Publicado: (2021) -
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022) -
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer
por: Na, Il-Kang, et al.
Publicado: (2015) -
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
por: Lang, Tonio Johannes Lukas, et al.
Publicado: (2023) -
P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
por: Le Coutre, Philipp, et al.
Publicado: (2023)